Business
-
Iliad Biotechnologies has licensed technology from Institut Pasteur de Lille, Inserm, National University of Singapore, and National University of Ireland Maynooth related to a live attenuated Bordetella pertussis vaccine, and the company says that it… Read more . . .
-
Civitas Therapeutics has announced the appointment of former MAP Pharmaceuticals CEO Timothy S. Nelson as Chairman of the board of directors. Nelson commented, “Civitas has a highly-validated drug inhalation platform, a potentially transformative Parkinson’s therapy… Read more . . .
-
Forest Laboratories has agreed to pay $2.9 billion cash for Aeroquin developer Aptalis. Aeroquin inhaled levofloxacin for the treatment of P. aeruginosa infections in CF patients, which is in Phase 3 development, was acquired by… Read more . . .
-
Aerogen and Philips have announced an agreement that “includes the acquisition of select assets solely related to Aerogen’s home-care business” by Philips. The announcement appears to refer to Aerogen’s Aeroneb Go vibrating mesh nebulizer. Philips… Read more . . .
-
Respira Therapeutics has announced that it will relocate to New Mexico after receiving new funding from Santa Fe-based Sun Mountain Capital and Cottonwood Technology Fund. The total amount of the investment from the venture capital… Read more . . .
-
Mylan has announced that it has acquired “exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist (LAMA) compound for various indications” from Pfizer, along with “multi-dose dry powder inhaler technology.” The… Read more . . .
-
Fresenius Kabi USA has announced the availability of 10 ml vials of 20% acetylcysteine inhalation solution. Acetylcysteine inhalation solution has been on the FDA’s drug shortage lists since 2011, in part due to a shutdown… Read more . . .
-
Retrophin has taken several steps toward development of intranasal oxytocin for the treatment of schizophrenia and autism, the company has announced. The biopharmaceutical company says that it will acquire Kyalin Biosciences and its lead product,… Read more . . .
-
GlaxoSmithKline has announced that it will invest approximately £200 million in UK manufacturing sites, including a new manufacturing facility in Ware for the Relvar Ellipta dry powder inhaler. The DPI was approved in Europe in… Read more . . .
-
According to United Therapeutics, the Office of the Inspector General of the US Department of Health and Human Services has subpoenaed documents related to the marketing of Tyvaso trepostinil inhalation solution for the treatment of… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden